Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
Authors:
Open Access
- 14 February 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 12 (1) , 73-77
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy that is characterized by a slowly progressive sensory and motor involvement lasting at least 2 months. We present a CIDP patient on subcutaneous Ig (SCIg). Upon fine-tuning his dose from 24 to 28 g/week, this showed a dramatic improvement in both hand grip (13–25%) and dorsiflexion (73–278%). Follow-up nerve conduction studies also demonstrated significant improvements in latencies, motor amplitudes, and conduction velocities. Ongoing surveillance of CIDP patients receiving SCIg therapy is therefore necessary to ensure therapeutic optimization.Keywords
This publication has 5 references indexed in Scilit:
- Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsCochrane Database of Systematic Reviews, 2017
- Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotypeJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency diseaseClinical and Experimental Immunology, 2015
- Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient.2013
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First RevisionJournal of the Peripheral Nervous System, 2010